DATASHEET
Host:
Rabbit
Target Protein:
FLT3 Tyr591
Modification Site:
Tyr591
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
2322
Source:
KLH conjugated synthetic phosphopeptide derived from human FLT3 around the phosphorylation site of Tyr591
Purification:
Purified by Protein A.
Storage Buffer:
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Background:
CD135 is a tyrosine kinase receptor expressed on normal cells including CD34+ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML BC. CD135, also known as FMS-like tyrosine kinase 3, FLT3, STK1, and Flk2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc. In humans, expression of Flt3 is restricted to subsets of CD34 positive as well as CD34 negative normal bone marrow cells. In these cells, the level of expression of Flt3 is rather low. Most of the CD34 bright Flt3+ cells co-express CD117 at high levels. They may represent early cycling, but not quiescent stem cells. Flt3+ cells in the CD34lo and CD34- populations do not co-express CD117 molecule and may represent B lymphoid precursors.
Conjugation:
Cy5.5
Excitation/ Emission:
675nm/694nm
Size:
100ul
Concentration:
1ug/ul
Applications:
WB(1:300-5000)
FCM(1:20-100)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
109
Human
Predicted Cross Reactive Species:
Mouse
For research use only. Not intended for diagnostic or therapeutic use.